NCT04566432 Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
| NCT ID | NCT04566432 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Geneplus-Beijing Co. Ltd. |
| Condition | Lung Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2020-07-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2020-07-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the predictive value of ctDNA in response, relapse for patients treated with immune checkpoint inhibitors or targeted therapy for ALK, ROS1, MET ex14 skipping.
Eligibility Criteria
Inclusion Criteria: * Provision of informed consent * Newly diagnosed and histological or cytological confirmed stage IIIB-IV lung adenocarcinoma or squamous cell carcinoma patients according to the AJCC staging system. The stage IV lung cancer and brain metastasis can be diagnosed by imaging and enhanced CT respectively * No EGFR mutation in tissue and ctDNA * Received immune checkpoint inhibitors as the first line therapy * ECOG performance status 0-2 with expected more than 6 months of survival time * Willingness to comply with required protocols and give permission to use the data for clinical research and products development Exclusion Criteria: * Patients have other primary cancers * Patients have symptomatic brain metastasis, complications that are associated with brain metastasis or cognitive disorders * Patients failed in either plasma or tissue sample QC
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04566432 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04566432 currently recruiting?
Yes, NCT04566432 is actively recruiting participants. Contact the research team at chenrr@geneplus.org.cn for enrollment information.
Where is the NCT04566432 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04566432 clinical trial?
NCT04566432 is sponsored by Geneplus-Beijing Co. Ltd.. The trial plans to enroll 250 participants.